{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:38:57Z","timestamp":1788745137301,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Reliable real-world data on direct acting anti-retroviral (DAA) uptake and treatment outcomes are lacking for patients with hepatitis C virus (HCV) in sub-Saharan Africa. This study provides data on HCV DAA-based treatment outcomes, mortality, loss-to-follow up, and associated factors among patients in Eritrea. A multicenter retrospective observational cohort study was conducted in two tertiary hospitals in Asmara, Eritrea. A structured checklist was used to collect data from patient\u2019s cards. Descriptive and inferential statistics used included means (\u00b1\u2009Standard deviation (SD), medians (Interquartile range (IQR), chi-squire (\u03c7\n                    <jats:sup>2<\/jats:sup>\n                    ), Kaplan\u2013Meier estimates, and multivariate Cox proportional hazard models. A total of 238 patients with median age of 59\u00a0years (IQR 50\u201369\u00a0years) were enrolled in the study. Out of the 227 patients initiated on treatment, 125 patients had viral load measurements at 12\u00a0weeks after end of treatment (EOT) whereas 102 patients had no viral load measurements at 12\u00a0weeks EOT. Among the patients with HCV RNA data post-EOT 12, 116 (92.8%) had sustained viral response (SVR). The prevalence of death and loss-to-follow up (LTFU) were (7.5%, 95% CI 1.7\u20134.1) and 67 (28.1%, 95% CI 22.3\u201333.9) translating into an incidence of 1.1 (95% CI 0.8\u20131.5) per 10,000 person days. Independent predictors of LTFU included the enrollment year (2020: aHR\u2009=\u20092.2, 95% CI 1\u20134.7;\n                    <jats:italic>p<\/jats:italic>\n                    value\u2009=\u20090.04); Hospital (Hospital B: aHR\u2009=\u20092.2, 95% CI 1\u20134.7;\n                    <jats:italic>p<\/jats:italic>\n                    value\u2009=\u20090.03) and the FIB-4 score (FIB-Score\u2009&lt;\u20091.45: aHR\u2009=\u20093.7, 95% CI 1.2\u201311.5;\n                    <jats:italic>p<\/jats:italic>\n                    value\u2009=\u20090.02). The SVR rates achieved in this cohort were high. However, high LTFU and high mortality driven largely by late presentation and suboptimal population screening\/case finding, were uncovered. These challenges can be addressed by test-and-treat programs that simultaneously prioritize programmatic screening, decentralization of care, and better patient tracking in the HCV care cascade.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-47258-7","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:02:48Z","timestamp":1701064968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea"],"prefix":"10.1038","volume":"13","author":[{"given":"Ghirmay Ghebrekidan","family":"Ghebremeskel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berhe Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver Okoth","family":"Achila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Tekle","family":"Mengistu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel Frezghi","family":"Asmelash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araia","family":"Berhane Mesfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Elfatih","family":"Hamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"47258_CR1","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3748\/wjg.v20.i11.2927","volume":"20","author":"VD Thong","year":"2014","unstructured":"Thong, V. D., Akkarathamrongsin, S., Poovorawan, K., Tangkijvanich, P. & Poovorawan, Y. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. World J. Gastroenterol. 20, 2927 (2014).","journal-title":"World J. Gastroenterol."},{"key":"47258_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/v13010041","volume":"13","author":"MA Martinez","year":"2020","unstructured":"Martinez, M. A. & Franco, S. Therapy implications of hepatitis C virus genetic diversity. Viruses 13, 41 (2020).","journal-title":"Viruses"},{"key":"47258_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00705-022-05375-0","volume":"167","author":"RJ Meshram","year":"2022","unstructured":"Meshram, R. J., Kathwate, G. H. & Gacche, R. N. Progress, evolving therapeutic\/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch. Virol. 167, 1\u201320 (2022).","journal-title":"Arch. Virol."},{"key":"47258_CR4","unstructured":"World Health Organization. Global hepatitis report 2017, https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ (2017)."},{"key":"47258_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3961\/jpmph.21.151","volume":"54","author":"N Brunner","year":"2021","unstructured":"Brunner, N. & Bruggmann, P. Trends of the global hepatitis C disease burden: Strategies to achieve elimination. J. Prev. Med. Public Health 54, 251 (2021).","journal-title":"J. Prev. Med. Public Health"},{"key":"47258_CR6","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3748\/wjg.v27.i29.4818","volume":"27","author":"BB Dennis","year":"2021","unstructured":"Dennis, B. B., Naji, L., Jajarmi, Y., Ahmed, A. & Kim, D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J. Gastroenterol. 27, 4818 (2021).","journal-title":"World J. Gastroenterol."},{"key":"47258_CR7","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection (2018)."},{"key":"47258_CR8","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.3748\/wjg.v27.i28.4603","volume":"27","author":"P Torre","year":"2021","unstructured":"Torre, P., Aglitti, A., Masarone, M. & Persico, M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J. Gastroenterol. 27, 4603 (2021).","journal-title":"World J. Gastroenterol."},{"key":"47258_CR9","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.3748\/wjg.v20.i11.2785","volume":"20","author":"S-W Chan","year":"2014","unstructured":"Chan, S.-W. Establishment of chronic hepatitis C virus infection: Translational evasion of oxidative defence. World J. Gastroenterol. 20, 2785 (2014).","journal-title":"World J. Gastroenterol."},{"key":"47258_CR10","doi-asserted-by":"publisher","first-page":"S745","DOI":"10.1093\/infdis\/jiaa534","volume":"222","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia, O. & Sulkowski, M. S. Hepatitis C virus treatment: Simplifying the simple and optimizing the difficult. J. Infect. Dis. 222, S745-s757. https:\/\/doi.org\/10.1093\/infdis\/jiaa534 (2020).","journal-title":"J. Infect. Dis."},{"key":"47258_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2036.2009.04061.x","volume":"30","author":"A Afendy","year":"2009","unstructured":"Afendy, A. et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment. Pharmacol. Ther. 30, 469\u2013476 (2009).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"47258_CR12","first-page":"1","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns, M. P. et al. Hepatitis C virus infection. Nat. Rev. Disease Primers 3, 1\u201319 (2017).","journal-title":"Nat. Rev. Disease Primers"},{"key":"47258_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.antiviral.2014.12.014","volume":"115","author":"TK Scheel","year":"2015","unstructured":"Scheel, T. K., Simmonds, P. & Kapoor, A. Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses. Antivir. Res. 115, 83\u201393 (2015).","journal-title":"Antivir. Res."},{"key":"47258_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4254\/wjh.v9.i33.1239","volume":"9","author":"R Taherkhani","year":"2017","unstructured":"Taherkhani, R. & Farshadpour, F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J. Hepatol. 9, 1239 (2017).","journal-title":"World J. Hepatol."},{"key":"47258_CR15","first-page":"3556780","volume":"2022","author":"V Green","year":"2022","unstructured":"Green, V. & Roytman, M. Treatment-resistant hepatitis C viral infection: A case report and literature review. Case Rep. Hepatol. 2022, 3556780 (2022).","journal-title":"Case Rep. Hepatol."},{"key":"47258_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/cid\/cir076","volume":"52","author":"BL Pearlman","year":"2011","unstructured":"Pearlman, B. L. & Traub, N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin. Infect. Dis. 52, 889\u2013900 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"47258_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons, B., Saleem, J., Heath, K., Cooke, G. S. & Hill, A. Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin. Infect. Dis. 61, 730\u2013740 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"47258_CR18","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030, https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/206453\/WHO_HIV_2016.04_eng.pdf (2016)."},{"key":"47258_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2055-6640(20)30329-0","volume":"3","author":"AM Hill","year":"2017","unstructured":"Hill, A. M., Nath, S. & Simmons, B. The road to elimination of hepatitis C: Analysis of cures versus new infections in 91 countries. J. Virus Erad. 3, 117\u2013123 (2017).","journal-title":"J. Virus Erad."},{"key":"47258_CR20","first-page":"613","volume":"63","author":"IW Apata","year":"2014","unstructured":"Apata, I. W. et al. Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection\u2014Sub-Saharan Africa, 2000\u20132011. Morb. Mortal. Wkly. Rep. 63, 613 (2014).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"47258_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12879-018-3174-x","volume":"18","author":"N Siraj","year":"2018","unstructured":"Siraj, N. et al. Seroprevalence of transfusion-transmissible infections among blood donors at National Blood Transfusion Service, Eritrea: A seven-year retrospective study. BMC Infect. Dis. 18, 264. https:\/\/doi.org\/10.1186\/s12879-018-3174-x (2018).","journal-title":"BMC Infect. Dis."},{"key":"47258_CR22","unstructured":"World Health Organization. WHO welcomes Egypt\u2019s support to 14 African countries in their fight against hepatitis C, https:\/\/www.afro.who.int\/news\/who-welcomes-egypts-support-14-african-countries-their-fight-against-hepatitis-c (2019)."},{"key":"47258_CR23","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/jvh.13399","volume":"27","author":"M van Dijk","year":"2020","unstructured":"van Dijk, M. & Drenth, J. P. H. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination. J. Viral Hepat. 27, 1270\u20131283. https:\/\/doi.org\/10.1111\/jvh.13399 (2020).","journal-title":"J. Viral Hepat."},{"key":"47258_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3855\/jidc.10190","volume":"12","author":"U Karic","year":"2018","unstructured":"Karic, U. et al. FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C\u2014A developing country\u2019s perspective in DAA era. J. Infect. Dev. Ctries 12, 178\u2013182. https:\/\/doi.org\/10.3855\/jidc.10190 (2018).","journal-title":"J. Infect. Dev. Ctries"},{"key":"47258_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3851\/imp3061","volume":"22","author":"A Arias","year":"2017","unstructured":"Arias, A. et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir. Ther. 22, 307\u2013312. https:\/\/doi.org\/10.3851\/imp3061 (2017).","journal-title":"Antivir. Ther."},{"key":"47258_CR26","first-page":"187","volume":"90","author":"P Mariantonietta","year":"2019","unstructured":"Mariantonietta, P., Antonio, R., Lorenzo, O. & Nicola, C. Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: A meta-analysis. Acta Bio Med. Atenei Parm. 90, 187 (2019).","journal-title":"Acta Bio Med. Atenei Parm."},{"key":"47258_CR27","doi-asserted-by":"publisher","first-page":"550205","DOI":"10.3389\/fphar.2020.550205","volume":"11","author":"S Mushtaq","year":"2020","unstructured":"Mushtaq, S. et al. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir\/velpatasvir in HCV genotype 3-infected patients: Real-world outcomes from Pakistan. Front. Pharmacol. 11, 550205. https:\/\/doi.org\/10.3389\/fphar.2020.550205 (2020).","journal-title":"Front. Pharmacol."},{"key":"47258_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-01837-y","volume":"21","author":"Y-T Huang","year":"2021","unstructured":"Huang, Y.-T. et al. Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol. 21, 1\u20139 (2021).","journal-title":"BMC Gastroenterol."},{"key":"47258_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s40506-020-00231-8","volume":"12","author":"MK Mohammed Abdul","year":"2020","unstructured":"Mohammed Abdul, M. K., Snyder, H. S., Chunduru, M., Lee, S. M. & Satapathy, S. K. Hepatitis C virus in the elderly in the direct-acting antiviral era: From diagnosis to cure. Curr. Treat. Options Infect. Dis. 12, 296\u2013309 (2020).","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"47258_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","volume":"4","author":"N Gupta","year":"2019","unstructured":"Gupta, N. et al. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir\u2013sofosbuvir (SHARED): A single-arm trial. Lancet Gastroenterol. Hepatol. 4, 119\u2013126 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"47258_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2147\/dddt.S130945","volume":"11","author":"F Mir","year":"2017","unstructured":"Mir, F., Kahveci, A. S., Ibdah, J. A. & Tahan, V. Sofosbuvir\/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des. Devel. Ther. 11, 497\u2013502. https:\/\/doi.org\/10.2147\/dddt.S130945 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"47258_CR32","doi-asserted-by":"publisher","first-page":"e17237","DOI":"10.7759\/cureus.17237","volume":"13","author":"R Ahmed","year":"2021","unstructured":"Ahmed, R. et al. Sofosbuvir\/Velpatasvir\u2014A promising treatment for chronic hepatitis C virus infection. Cureus 13, e17237. https:\/\/doi.org\/10.7759\/cureus.17237 (2021).","journal-title":"Cureus"},{"key":"47258_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","volume":"65","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J. Hepatol. 65, 33\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.042 (2016).","journal-title":"J. Hepatol."},{"key":"47258_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40121-020-00329-y","volume":"9","author":"M Atsukawa","year":"2020","unstructured":"Atsukawa, M. et al. Real-world clinical application of 12-week sofosbuvir\/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: A prospective, multicenter study. Infect. Dis. Ther. 9, 851\u2013866. https:\/\/doi.org\/10.1007\/s40121-020-00329-y (2020).","journal-title":"Infect. Dis. Ther."},{"key":"47258_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge, P. S. & Runyon, B. A. Treatment of patients with cirrhosis. N. Engl. J. Med. 375, 767\u2013777 (2016).","journal-title":"N. Engl. J. Med."},{"key":"47258_CR36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.cmi.2016.08.025","volume":"22","author":"LB Dustin","year":"2016","unstructured":"Dustin, L. B., Bartolini, B., Capobianchi, M. R. & Pistello, M. Hepatitis C virus: Life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin. Microbiol. Infect. 22, 826\u2013832. https:\/\/doi.org\/10.1016\/j.cmi.2016.08.025 (2016).","journal-title":"Clin. Microbiol. Infect."},{"key":"47258_CR37","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","volume":"2","author":"MW Sonderup","year":"2017","unstructured":"Sonderup, M. W. et al. Hepatitis C in sub-Saharan Africa: The current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol. Hepatol. 2, 910\u2013919 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"47258_CR38","doi-asserted-by":"publisher","first-page":"e029743","DOI":"10.1136\/bmjopen-2019-029743","volume":"9","author":"J Umutesi","year":"2019","unstructured":"Umutesi, J. et al. Screening a nation for hepatitis C virus elimination: A cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open 9, e029743. https:\/\/doi.org\/10.1136\/bmjopen-2019-029743 (2019).","journal-title":"BMJ Open"},{"key":"47258_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/jvh.13405","volume":"28","author":"Y Min Thaung","year":"2021","unstructured":"Min Thaung, Y. et al. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and\/or hepatitis B virus-co-infected patients in Myanmar. J. Viral Hepat. 28, 147\u2013158. https:\/\/doi.org\/10.1111\/jvh.13405 (2021).","journal-title":"J. Viral Hepat."},{"key":"47258_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0969-3","volume":"15","author":"C Yek","year":"2017","unstructured":"Yek, C. et al. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: A retrospective cohort study. BMC Med. 15, 1\u20138 (2017).","journal-title":"BMC Med."},{"key":"47258_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12954-021-00486-4","volume":"18","author":"J Ziff","year":"2021","unstructured":"Ziff, J. et al. Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City. Harm. Reduct. J. 18, 38. https:\/\/doi.org\/10.1186\/s12954-021-00486-4 (2021).","journal-title":"Harm. Reduct. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47258-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:12:17Z","timestamp":1701065537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47258"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47258-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1818948\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20792"}}